Molecular epidemiology of Acinetobacter baumannii during COVID-19 at a hospital in northern China.


Journal

Annals of clinical microbiology and antimicrobials
ISSN: 1476-0711
Titre abrégé: Ann Clin Microbiol Antimicrob
Pays: England
ID NLM: 101152152

Informations de publication

Date de publication:
18 Jul 2024
Historique:
received: 21 09 2023
accepted: 10 06 2024
medline: 19 7 2024
pubmed: 19 7 2024
entrez: 18 7 2024
Statut: epublish

Résumé

The wide spread of carbapenem-resistance clones of Acinetobacter baumannii has made it a global public problem. Some studies have shown that the prevalence of Acinetobacter baumannii clones can change over time. However, few studies with respect to the change of epidemiological clones in Acinetobacter baumannii during Corona Virus Disease 2019 (COVID-19) were reported. This study aims to investigate the molecular epidemiology and resistance mechanisms of Acinetobacter baumannii during COVID-19. A total of 95 non-replicated Acinetobacter baumannii isolates were enrolled in this study, of which 60.0% (n = 57) were identified as carbapenem-resistant Acinetobacter baumannii (CRAB). The positive rate of the bla The prevalent clones of Acinetobacter baumannii in our organization have changed during COVID-19, which was different from that of China. ST540 strains which carried multiple drug-resistant mobile elements was spreading, indicating that it is essential to strengthen the molecular epidemiology of Acinetobacter baumannii.

Sections du résumé

BACKGROUND BACKGROUND
The wide spread of carbapenem-resistance clones of Acinetobacter baumannii has made it a global public problem. Some studies have shown that the prevalence of Acinetobacter baumannii clones can change over time. However, few studies with respect to the change of epidemiological clones in Acinetobacter baumannii during Corona Virus Disease 2019 (COVID-19) were reported. This study aims to investigate the molecular epidemiology and resistance mechanisms of Acinetobacter baumannii during COVID-19.
RESULTS RESULTS
A total of 95 non-replicated Acinetobacter baumannii isolates were enrolled in this study, of which 60.0% (n = 57) were identified as carbapenem-resistant Acinetobacter baumannii (CRAB). The positive rate of the bla
CONCLUSION CONCLUSIONS
The prevalent clones of Acinetobacter baumannii in our organization have changed during COVID-19, which was different from that of China. ST540 strains which carried multiple drug-resistant mobile elements was spreading, indicating that it is essential to strengthen the molecular epidemiology of Acinetobacter baumannii.

Identifiants

pubmed: 39026334
doi: 10.1186/s12941-024-00716-0
pii: 10.1186/s12941-024-00716-0
doi:

Substances chimiques

beta-Lactamases EC 3.5.2.6
Anti-Bacterial Agents 0
Carbapenems 0
Bacterial Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

63

Subventions

Organisme : the State Key Laboratory of Pathogen and Biosecurity of China
ID : SKLPBS2228

Informations de copyright

© 2024. The Author(s).

Références

Almasaudi SB. Acinetobacter spp. as nosocomial pathogens: epidemiology and resistance features. Saudi J Biol Sci. 2018;25(3):586–96.
doi: 10.1016/j.sjbs.2016.02.009 pubmed: 29686523
Lee CR, Lee JH, Park M, Park KS, Bae IK, Kim YB, et al. Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol. 2017;7:55.
doi: 10.3389/fcimb.2017.00055 pubmed: 28348979 pmcid: 5346588
Paterson DL, Bonomo RA. Multidrug-resistant gram-negative pathogens: the Urgent need for ‘Old’ polymyxins. Adv Exp Med Biol. 2019;1145:9–13.
doi: 10.1007/978-3-030-16373-0_2 pubmed: 31364068
Nasr P. Genetics, epidemiology, and clinical manifestations of multidrug-resistant Acinetobacter baumannii. J Hosp Infect. 2020;104(1):4–11.
doi: 10.1016/j.jhin.2019.09.021 pubmed: 31589900
Li T, Luo D, Ning N, Liu X, Chen F, Zhang L, et al. Acinetobacter baumannii adaptation to the host pH microenvironment is mediated by allelic variation in a single residue of BauA protein. PNAS Nexus. 2023;2(4):pgad079.
doi: 10.1093/pnasnexus/pgad079 pubmed: 37065616 pmcid: 10098034
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–27.
doi: 10.1016/S1473-3099(17)30753-3 pubmed: 29276051
Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis. 2010;16(1):35–40.
doi: 10.3201/eid1601.090852 pubmed: 20031040 pmcid: 2874364
Huang ZY, Li J, Shui J, Wang HC, Hu YM, Zou MX. Co-existence of blaOXA-23 and blaVIM in carbapenem-resistant Acinetobacter baumannii isolates belonging to global complex 2 in a Chinese teaching hospital. Chin Med J (Engl). 2019;132(10):1166–72.
doi: 10.1097/CM9.0000000000000193 pubmed: 30882466
Hamidian M, Nigro SJ. Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii. Microb Genom. 2019;5(10).
Thomas CM, Nielsen KM. Mechanisms of, and barriers to, horizontal gene transfer between bacteria. Nat Rev Microbiol. 2005;3(9):711–21.
doi: 10.1038/nrmicro1234 pubmed: 16138099
Nigro SJ, Hall RM. Structure and context of Acinetobacter transposons carrying the oxa23 carbapenemase gene. J Antimicrob Chemother. 2016;71(5):1135–47.
doi: 10.1093/jac/dkv440 pubmed: 26755496
Khongfak S, Thummeepak R, Leungtongkam U, Tasanapak K, Thanwisai A, Sitthisak S. Insights into mobile genetic elements and the role of conjugative plasmid in transferring aminoglycoside resistance in extensively drug-resistant Acinetobacter baumannii AB329. PeerJ. 2022;10:e13718.
doi: 10.7717/peerj.13718 pubmed: 35855908 pmcid: 9288165
Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A. 1998;95(6):3140–5.
doi: 10.1073/pnas.95.6.3140 pubmed: 9501229 pmcid: 19708
Pérez-Losada M, Cabezas P, Castro-Nallar E, Crandall KA. Pathogen typing in the genomics era: MLST and the future of molecular epidemiology. Infect Genet Evol. 2013;16:38–53.
doi: 10.1016/j.meegid.2013.01.009 pubmed: 23357583
Bessell PR, Rotariu O, Innocent GT, Smith-Palmer A, Strachan NJ, Forbes KJ, et al. Using sequence data to identify alternative routes and risk of infection: a case-study of campylobacter in Scotland. BMC Infect Dis. 2012;12:80.
doi: 10.1186/1471-2334-12-80 pubmed: 22462563 pmcid: 3340322
De Francesco MA, Caracciolo S, Gargiulo F, Manca N. Phenotypes, genotypes, serotypes and molecular epidemiology of erythromycin-resistant Streptococcus agalactiae in Italy. Eur J Clin Microbiol Infect Dis. 2012;31(8):1741–7.
doi: 10.1007/s10096-011-1495-4 pubmed: 22120421
Kong X, Chen T, Guo L, Zhou Y, Lu P, Xiao Y. Phenotypic and genomic comparison of dominant and nondominant sequence-type of Acinetobacter baumannii isolated in China. Front Cell Infect Microbiol. 2023;13:1118285.
doi: 10.3389/fcimb.2023.1118285 pubmed: 36891157 pmcid: 9986592
Niu T, Guo L, Kong X, He F, Ru C, Xiao Y. Prevalent Dominant Acinetobacter baumannii ST191/195/208 strains in bloodstream infections have high Drug Resistance and Mortality. Infect Drug Resist. 2023;16:2417–27.
doi: 10.2147/IDR.S403604 pubmed: 37138832 pmcid: 10149779
Zarrilli R, Bagattini M, Migliaccio A, Esposito EP, Triassi M. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in Italy. Ann Ig. 2021;33(5):401–9.
pubmed: 33270079
Oikonomou O, Sarrou S, Papagiannitsis CC, Georgiadou S, Mantzarlis K, Zakynthinos E, et al. Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: mechanisms of resistance, molecular identification and epidemiological data. BMC Infect Dis. 2015;15:559.
doi: 10.1186/s12879-015-1297-x pubmed: 26653099 pmcid: 4675053
McKay SL, Vlachos N, Daniels JB, Albrecht VS, Stevens VA, Rasheed JK, et al. Molecular Epidemiology of Carbapenem-Resistant Acinetobacter baumannii in the United States, 2013–2017. Microb Drug Resist. 2022;28(6):645–53.
doi: 10.1089/mdr.2021.0352 pubmed: 35639112
Frenk S, Temkin E, Lurie-Weinberger MN, Keren-Paz A, Rov R, Rakovitsky N, et al. Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance. J Antimicrob Chemother. 2022;77(4):934–43.
doi: 10.1093/jac/dkac010 pubmed: 35084023
Kim SE, Choi SM, Yu Y, Shin SU, Oh TH, Kang SJ, et al. Replacement of the Dominant ST191 clone by ST369 among Carbapenem-Resistant Acinetobacter baumannii Bloodstream isolates at a Tertiary Care Hospital in South Korea. Front Microbiol. 2022;13:949060.
doi: 10.3389/fmicb.2022.949060 pubmed: 35910596 pmcid: 9335038
Ning NZ, Liu X, Bao CM, Chen SM, Cui EB, Zhang JL, et al. Molecular epidemiology of bla (OXA-23) -producing carbapenem-resistant Acinetobacter baumannii in a single institution over a 65-month period in north China. BMC Infect Dis. 2017;17(1):14.
doi: 10.1186/s12879-016-2110-1 pubmed: 28056839 pmcid: 5217423
Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19(5):455–77.
doi: 10.1089/cmb.2012.0021 pubmed: 22506599 pmcid: 3342519
Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014;30(14):2068–9.
doi: 10.1093/bioinformatics/btu153 pubmed: 24642063
Price MN, Dehal PS, Arkin AP. FastTree 2–approximately maximum-likelihood trees for large alignments. PLoS ONE. 2010;5(3):e9490.
doi: 10.1371/journal.pone.0009490 pubmed: 20224823 pmcid: 2835736
Zhou H, Zhang T, Yu D, Pi B, Yang Q, Zhou J, et al. Genomic analysis of the multidrug-resistant Acinetobacter baumannii strain MDR-ZJ06 widely spread in China. Antimicrob Agents Chemother. 2011;55(10):4506–12.
doi: 10.1128/AAC.01134-10 pubmed: 21788470 pmcid: 3187012
Letunic I, Bork P. Interactive tree of life (iTOL) v5: an online tool for phylogenetic tree display and annotation. Nucleic Acids Res. 2021;49(W1):W293–6.
doi: 10.1093/nar/gkab301 pubmed: 33885785 pmcid: 8265157
Ribeiro-Gonçalves B, Francisco AP, Vaz C, Ramirez M, Carriço JA. PHYLOViZ Online: web-based tool for visualization, phylogenetic inference, analysis and sharing of minimum spanning trees. Nucleic Acids Res. 2016;44(W1):W246–51.
doi: 10.1093/nar/gkw359 pubmed: 27131357 pmcid: 4987911
Florensa AF, Kaas RS, Clausen P, Aytan-Aktug D, Aarestrup FM. ResFinder - an open online resource for identification of antimicrobial resistance genes in next-generation sequencing data and prediction of phenotypes from genotypes. Microb Genom. 2022;8(1).
Wang M, Goh YX, Tai C, Wang H, Deng Z, Ou HY. VRprofile2: detection of antibiotic resistance-associated mobilome in bacterial pathogens. Nucleic Acids Res. 2022;50(W1):W768–73.
doi: 10.1093/nar/gkac321 pubmed: 35524563 pmcid: 9252795
Darling AC, Mau B, Blattner FR, Perna NT. Mauve: multiple alignment of conserved genomic sequence with rearrangements. Genome Res. 2004;14(7):1394–403.
doi: 10.1101/gr.2289704 pubmed: 15231754 pmcid: 442156
Alikhan NF, Petty NK, Ben Zakour NL, Beatson SA. BLAST Ring Image Generator (BRIG): simple prokaryote genome comparisons. BMC Genomics. 2011;12:402.
doi: 10.1186/1471-2164-12-402 pubmed: 21824423 pmcid: 3163573
Siguier P, Perochon J, Lestrade L, Mahillon J, Chandler M. ISfinder: the reference centre for bacterial insertion sequences. Nucleic Acids Res. 2006;34(Database issue):D32–6.
doi: 10.1093/nar/gkj014 pubmed: 16381877
Hu F, Yuan L, Yang Y, Xu Y, Huang Y, Hu Y, et al. A multicenter investigation of 2,773 cases of bloodstream infections based on China antimicrobial surveillance network (CHINET). Front Cell Infect Microbiol. 2022;12:1075185.
doi: 10.3389/fcimb.2022.1075185 pubmed: 36590586 pmcid: 9798236
Jiang M, Chen X, Liu S, Zhang Z, Li N, Dong C, et al. Epidemiological analysis of Multidrug-Resistant Acinetobacter baumannii isolates in a Tertiary Hospital over a 12-Year period in China. Front Public Health. 2021;9:707435.
doi: 10.3389/fpubh.2021.707435 pubmed: 34458227 pmcid: 8388840
Pournaras S, Koumaki V, Gennimata V, Kouskouni E, Tsakris A. In Vitro Activity of Tigecycline against Acinetobacter baumannii: Global Epidemiology and resistance mechanisms. Adv Exp Med Biol. 2016;897:1–14.
pubmed: 26563303
Al-Sweih NA, Al-Hubail MA, Rotimi VO. Emergence of tigecycline and colistin resistance in Acinetobacter species isolated from patients in Kuwait hospitals. J Chemother. 2011;23(1):13–6.
doi: 10.1179/joc.2011.23.1.13 pubmed: 21482488
Sun C, Yu Y, Hua X. Resistance mechanisms of tigecycline in Acinetobacter baumannii. Front Cell Infect Microbiol. 2023;13:1141490.
doi: 10.3389/fcimb.2023.1141490 pubmed: 37228666 pmcid: 10203620
Guo Y, Han R, Jiang B, Ding L, Yang F, Zheng B, et al. In Vitro Activity of New β-Lactam-β-Lactamase inhibitor combinations and comparators against clinical isolates of Gram-negative Bacilli: results from the China Antimicrobial Surveillance Network (CHINET) in 2019. Microbiol Spectr. 2022;10(4):e0185422.
doi: 10.1128/spectrum.01854-22 pubmed: 35862963
Zhu L, Yan Z, Zhang Z, Zhou Q, Zhou J, Wakeland EK, et al. Complete genome analysis of three Acinetobacter baumannii clinical isolates in China for insight into the diversification of drug resistance elements. PLoS ONE. 2013;8(6):e66584.
doi: 10.1371/journal.pone.0066584 pubmed: 23826102 pmcid: 3691203
Shi X, Wang H, Wang X, Jing H, Duan R, Qin S, et al. Molecular characterization and antibiotic resistance of Acinetobacter baumannii in cerebrospinal fluid and blood. PLoS ONE. 2021;16(2):e0247418.
doi: 10.1371/journal.pone.0247418 pubmed: 33617547 pmcid: 7899338
You Q, Du X, Hu N, Zhang Y, Zhang N, Wang F, et al. Local characteristics of molecular epidemiolgy of Acinetobacter baumannii in Jilin province (northeast China). BMC Microbiol. 2023;23(1):19.
doi: 10.1186/s12866-023-02761-9 pubmed: 36658486 pmcid: 9850558
Ibrahim S, Al-Saryi N, Al-Kadmy IMS, Aziz SN. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Mol Biol Rep. 2021;48(10):6987–98.
doi: 10.1007/s11033-021-06690-6 pubmed: 34460060 pmcid: 8403534
Bharathi SV, Venkataramaiah M, Rajamohan G. Genotypic and phenotypic characterization of Novel sequence types of Carbapenem-Resistant Acinetobacter baumannii, with heterogeneous resistance determinants and targeted variations in Efflux Operons. Front Microbiol. 2021;12:738371.
doi: 10.3389/fmicb.2021.738371 pubmed: 35002996 pmcid: 8735875
Lv W, Zhang X, Hou M, Han D, Li Y, Xiong W. Draft genome sequence of an OXA-23, OXA-66, ADC-25 and TEM-1D co-producing Acinetobacter baumannii ST195 isolated from a patient with neonatal pneumonia in China. J Glob Antimicrob Resist. 2019;16:1–3.
doi: 10.1016/j.jgar.2018.11.008 pubmed: 30445210
Liu LL, Ji SJ, Ruan Z, Fu Y, Fu YQ, Wang YF, et al. Dissemination of blaOXA-23 in Acinetobacter spp. in China: main roles of conjugative plasmid pAZJ221 and transposon Tn2009. Antimicrob Agents Chemother. 2015;59(4):1998–2005.
doi: 10.1128/AAC.04574-14 pubmed: 25605357 pmcid: 4356780
Hu Y, Zhang X, Deng S, Yue C, Jia X, Lyu Y. Non-antibiotic prevention and treatment against Acinetobacter baumannii infection: are vaccines and adjuvants effective strategies? Front Microbiol. 2023;14:1049917.
doi: 10.3389/fmicb.2023.1049917 pubmed: 36760499 pmcid: 9905804
Yoon EJ, Kim JO, Yang JW, Kim HS, Lee KJ, Jeong SH, et al. The blaOXA-23-associated transposons in the genome of Acinetobacter spp. represent an epidemiological situation of the species encountering carbapenems. J Antimicrob Chemother. 2017;72(10):2708–14.
doi: 10.1093/jac/dkx205 pubmed: 29091183

Auteurs

Xinlin Huang (X)

State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, No. 20 Dongda Street, Fengtai District, Beijing, 100071, China.
Department of Clinical Laboratory, the Fifth Medical Center, Chinese Peoples's Liberation Army (PLA) General Hospital, No. 100 Western 4th Middle Ring Road, Beijing, 100039, China.
School of Medical Laboratory, Weifang Medical University, Weifang, 261053, China.

Nianzhi Ning (N)

State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, No. 20 Dongda Street, Fengtai District, Beijing, 100071, China.

Deyu Li (D)

State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, No. 20 Dongda Street, Fengtai District, Beijing, 100071, China.

Suming Chen (S)

Department of Clinical Laboratory, the Fifth Medical Center, Chinese Peoples's Liberation Army (PLA) General Hospital, No. 100 Western 4th Middle Ring Road, Beijing, 100039, China.

Liangyan Zhang (L)

State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, No. 20 Dongda Street, Fengtai District, Beijing, 100071, China.

Huan Wang (H)

Department of Clinical Laboratory, the Fifth Medical Center, Chinese Peoples's Liberation Army (PLA) General Hospital, No. 100 Western 4th Middle Ring Road, Beijing, 100039, China.

Chunmei Bao (C)

Department of Clinical Laboratory, the Fifth Medical Center, Chinese Peoples's Liberation Army (PLA) General Hospital, No. 100 Western 4th Middle Ring Road, Beijing, 100039, China.

Xiaolan Yang (X)

State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, No. 20 Dongda Street, Fengtai District, Beijing, 100071, China.

Boan Li (B)

Department of Clinical Laboratory, the Fifth Medical Center, Chinese Peoples's Liberation Army (PLA) General Hospital, No. 100 Western 4th Middle Ring Road, Beijing, 100039, China. lba@263.net.
School of Medical Laboratory, Weifang Medical University, Weifang, 261053, China. lba@263.net.

Hui Wang (H)

State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, No. 20 Dongda Street, Fengtai District, Beijing, 100071, China. geno0109@vip.sina.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH